Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
for Recurrent B Acute Lymphoblastic Leukemia
156 locations incl. Birmingham
Sponsor: Children's Oncology Group
Sex: All·Age: 1 - 21
Code: NCT02981628·Phase 2·Recruiting